A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509357-31-00

Acronym

BP42230

Enrollment

Registered

2024-03-15

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis (MS)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Germany, Italy, Poland, Portugal, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026